hiv-1 integrase

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

(S)-BI-1001 is an active S-enantiomer of BI-1001. (S)-BI-1001 has antiviral potency against HIV-1 integrase (IC50: 28 nM, and EC50: 450 nM and a Kd: 4.7 μM).

Lavendustin B is a Tyrosine Kinase Inhibitor and an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

HIV-1 integrase inhibitor 7 is a potent inhibitor of HIV-1 integrase (IC50: 33.3 nM).

Hiv-1 integrase inhibitor is an effective anti-HIV drug.

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 integrase inhibitor 4 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV-1integrase inhibitor 12 (Compound 17) is an inhibitor of HIV-1 integrase with an IC50 of 1.4 nM. It effectively inhibits both HIV-1WT and HIV-1T125A with IC50 values of 7.4 nM and 120 nM, respectively. This compound exhibits metabolic stability and Caco-2 permeability in rats, with favorable pharmacokinetic properties, including good bioavailability (64%) and low clearance rate (0.16 L/hr/kg).

HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor of HIV-1 integrase, with an IC50 value of 1.8 nM. It can inhibit HIV-1WT and HIV-1T125A, with IC50 values of 21 and 580 nM, respectively.

HIV-1 integrase inhibitor 9 (compound 8a) is a potent inhibitor of HIV-1 RNase H (IC50: 12.3 μM) with antiviral effects.

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

HIV-1 integrase inhibitor 11 (compound 5) effectively inhibits HIV-1 integrase (HIV-1integrase), with an IC50 of 125 μM.

GSK-364735 is a human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitor with antiviral activity and is used in the study of retroviral infections.

Dolutegravir intermediate-1 (1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid) is a new synthetic Dolutegravir intermediate. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.

AI 3-16787 is an HIV-1 integrase inhibitor exhibiting inhibitory activity against strand transfer in the presence of Mn²⁺.

Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Bictegravir Sodium (GS-9883 Sodium) is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir Sodium exhibits potent and selective anti-HIV activity and low cytotoxicity

Cabotegravir (S/GSK1265744) (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).

Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Equisetin, an N-methylserine-derived acyl tetramic acid isolated from the terrestrial fungus Fusarium equiseti NRRL 5537, functions as a Quorum-sensing inhibitor (QSI) that specifically attenuates QS-regulated virulence phenotypes in P. aeruginosa, presenting a potent lead for treating P. aeruginosa infections without hindering bacterial growth. This tetramate-containing natural product possesses antibiotic and cytotoxic properties, effectively inhibiting the growth of Gram-positive bacteria and HIV-1 integrase activity, yet it does not impact Gram-negative bacteria.

BI 224436 is an inhibitor of HIV-1 noncatalytic site integrase. With EC50 values of less than 15 nM against different HIV-1 laboratory strains.

HIV-1 integrase inhibitor 2 is used for the treatment of human immunodeficiency virus (HIV) infection.

BMIM-TFSI (compound8) is an HIV-1 integrase inhibitor that effectively suppresses both the 3'-processing (3'-P) and strand transfer (ST) steps of the integration process. It is applicable in HIV-1 research.

HIV-1inhibitor-63 (compound S17) is a potent inhibitor of HIV-1. It effectively suppresses the formation of the integrase-Ku70 complex with an IC50 value of 12 µM. Additionally, HIV-1inhibitor-63 impedes the post-integration DNA repair of HIV-1.